Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Olsalazine (2 g/day) compared with placebo (very low certainty).
1 finding from 1 review
- Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 0.36 [0.18, 0.71]1 study · 91 participantsVery low